UBS (NYSE:UBS) believes Research in Motion’s (NASDAQ:RIMM) near-term M&A options are less viable near-term given accelerating U.S. losses and likely another weak quarter. The firm believes any potential acquirer will want to see the business stabilize before pursuing the company.Shares are Neutral rated with a $15.50 price target.Research In Motion (NASDAQ:RIMM) has potential upside of 32.1% based on a current price of $15.35 and an average consensus analyst price target of $20.27.
